Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at nearly 3 years, according ...
Rintatolimod (Ampligen) combined with durvalumab (Imfinzi) has continued to exhibit encouraging efficacy, safety, and ...
Although not as essential as in other tumor types, genomic testing is increasingly playing a role in guiding treatment for advanced sarcoma.
Although patients who received tumor-infiltrating lymphocyte (TIL) therapy had favorable overall survival (OS), a significant number who were evaluated to receive lifileucel (Amtagvi) did not get ...
EB103 utilizes Eureka’s ARTEMIS technology, a platform designed to harness the human immune system more effectively than standard therapies. The ARTEMIS T cells are engineered to address the specific ...
The FDA has approved a label update for axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed autologous T-cell immunotherapy. This update removes previous Limitations of Use for patients with ...
Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results